A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems

(2010) C. CAMMÀ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study

(2009) Jean-Claude Barbare et al.   EUROPEAN JOURNAL OF CANCER

Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials

(2009) Josep M. Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE

(2009) J. Bruix et al.   JOURNAL OF HEPATOLOGY

Major achievements in hepatocellular carcinoma

(2009) Jordi Bruix et al.   LANCET

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies

(2009) Puneeta Tandon et al.   LIVER INTERNATIONAL

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE